EUSA Pharma announce acquisition of SYLVANT® from Janssen

EUSA Pharma acquires SYLVANT from Janssen for $115 million

BioIVT acquires Optivia Biotechnology

BioIVT, a provider of research models and services for drug development, has announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its...

Sanofi and Advent finalise negotiations for the acquisition of Zentiva

Sanofi and Advent International (Advent) have finished negotiations for the acquisition of Zentiva - Sanofi's European generics business. Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion...

Takeda ups bid to $65 billion in negotiations to buy Shire

Takeda has increased offer to buy Shire for a mix of stock and cash worth ~$65 billion

Merck to sell Consumer Health to Procter & Gamble

Merck has sold its global Consumer Health business to Procter & Gamble

Advent in negotiations to acquire Sanofi’s generics business

Advent and Sanofi are in negotiations under which Advent would acquire Zentiva,

Certara acquires Analytica Laser

Certara announced it has acquired Analytica Laser which uses health economics and outcomes research (HEOR)

Mylan partners with Fujifilm Kyowa Kirin Biologics

Mylan partners with Fujifilm Kyowa Kirin Biologics to commercialise a biosimilar to Humira®

GSK buys out Novartis’ stake in Consumer Healthcare

GlaxoSmithKline plc have announced that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint...

Nanologica & Sterling partnership furthers new business venture

Nanologica AB has entered into a service agreement with global contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions for the large-scale production of...

Latest articles

Woman undergoing breast checks with doctor to show NICE recommends new early breast cancer treatment

Novartis’ Kisqali® shows overall survival benefit in advanced breast cancer

Novartis has announced a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials, reinforcing the overall survival (OS) benefit of Kisqali®...
Image of a rocket launching from a laptop keyboard to show Pf Webinars: Adopting Agile for more effective cross-functional marketing teamwork

Pf Webinar: Adopting Agile in pharma for more effective cross-functional marketing teamwork

Pf is proud to announce the second instalment of the FREE webinar series with Triducive. This webinar focuses on Agile and how it can...
Doctor writing notes to show New Patient Recruitment Centres for late-phase clinical research

New Patient Recruitment Centres for late-phase clinical research

NHS patients will benefit from easier access to clinical research opportunities, following a £7m government investment to launch five new regional Patient Recruitment Centres...

Popular articles

Image of a hand holding a torch to show Kate Bingham appointed Chair of UK Vaccine Taskforce

Kate Bingham appointed Chair of UK Vaccine Taskforce

Kate Bingham has been appointed Chair of the UK’s Vaccine Taskforce – the group set up by the Government’s Chief Scientific Adviser, Deputy Chief...
Woman undergoing breast checks with doctor to show NICE recommends new early breast cancer treatment

Novartis’ Kisqali® shows overall survival benefit in advanced breast cancer

Novartis has announced a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials, reinforcing the overall survival (OS) benefit of Kisqali®...
Image of a robot holding a medical bag to show Digital transformation in the NHS

Digital transformation in the NHS

A new report by the National Audit Office (NAO) on digital transformation in the NHS has found that recent investment in digital transformation has...
Image of a medical professional in PPE with medical equipment to show BIVDA comments on Roche COVID-19 antibody test authorisation in England

BIVDA comments on Roche COVID-19 antibody test authorisation

The British In Vitro Diagnostics Association (BIVDA) has commented on the Roche COVID-19 antibody test authorisation by Public Health England. BIVDA is delighted to see...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription